50 completed, 10 unknown, 4 terminated, 1 active not recruiting. 69 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 69 | Completed 50, Unknown 10, Terminated 4, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1, Suspended 1, Withdrawn 1 |
Follow Telmisartan: new trials by email Literature Review of Telmisartan trials Research Report on Telmisartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension Eplerenone, Telmisartan - Hypertension (HTN), Low-Renin Essential Hypertension | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 128 | 2026-12-01 | 2026-11-20 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg - Essential Hypertension | Phase 4 | Active not recruiting | Yuhan Corporation | 198 | 2023-10-18 | 2026-02-13 |
| A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome Telmisartan, Losartan - Essential Hypertension, Metabolic Syndrome | Phase 4 | Unknown | Chong Kun Dang Pharmaceutical | 116 | 2023-06-01 | 2023-05-06 |
| Efficacy and Safety of Telmisartan Compared With Losartan telmisartan, Losartan - Diabetic Nephropathies, Hypertension | Phase 4 | Unknown | Chong Kun Dang Pharmaceutical | 98 | 2023-04-19 | 2024-05-28 |
| Occurrence of Dyskalemia With Treatment for Hypertension Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg - Hypertension, Potassium Imbalance | Phase 4 | Completed | National Heart Foundation of Bangladesh | 1090 | 2022-01-15 | 2023-07-14 |
| Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Angiotensin Receptor Blockers, Placebo - Coronavirus Disease 2019, COVID-19 | Phase 4 | Completed | The George Institute | 787 | 2020-06-19 | 2022-03-17 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria Telmisartan/Rosuvastatin 40/10mg, Telmisartan 40mg - Chronic Kidney Disease, Proteinuria | Phase 4 | Unknown | Yuhan Corporation | 374 | 2018-06-05 | 2020-12-14 |
| Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) Linagliptin, Empagliflozin, Telmisartan - Diabetic Nephropathy Type 2 | Phase 4 | Withdrawn | Steno Diabetes Center Copenhagen | 2017-11-15 | 2018-09-14 | |
| Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension Duowell®, Telmisartan - Hypertension, Dyslipidemia | Phase 4 | Completed | Yuhan Corporation | 80 | 2017-09-11 | 2021-04-06 |
| A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome Telmisartan 40mg + Rosuvastatin 20mg, Telmisartan 80mg + Rosuvastatin 20mg, Telmisartan 40mg, 80 mg - Metabolic Syndrome | Phase 4 | Terminated | Yuhan Corporation | 55 | 2016-10-01 | 2019-04-12 |
| S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension S-amlodipine 2.5mg + Chlorthalidone 25mg, S-amlodipine 2.5mg + Telmisartan 40mg - Essential Hypertension | Phase 4 | Unknown | Seoul National University Bundang Hospital | 170 | 2015-12-02 | 2017-07-21 |
| Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation Telmisartan 80 mg and amlodipine 5 mg, Placebo (for telmisartan and amlodipine) - Atrial Fibrillation | Phase 4 | Completed | Research Institute for Complex Problems of Cardiovascular Diseases, Russia | 64 | 2015-11-01 | 2017-03-22 |
| INTERVENCION Trial Hydrochlorothiazide, Amlodipine, Telmisartan - Blood Pressure, High | Phase 4 | Completed | Prevencion | 166 | 2014-09-01 | 2025-07-29 |
| Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Perindopril, Telmisartan, Amlodipine - Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 4 | Unknown | Nanfang Hospital, Southern Medical University | 180 | 2014-08-01 | 2014-08-11 |
| The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy Telminuvo®Tab. 40/2.5mg, Telmitrend®Tab. 80mg - Hypertension | Phase 4 | Completed | Chong Kun Dang Pharmaceutical | 217 | 2014-06-01 | 2020-01-31 |
| A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R Azilsartan, Telmisartan - Essential Hypertension Complicated by Type 2 Diabetes Mellitus | Phase 4 | Completed | Takeda | 33 | 2014-06-01 | 2017-08-02 |
| Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms Telmisartan, Placebo - Abdominal Aortic Aneurysm | Phase 4 | Completed | Palo Alto Veterans Institute for Research | 22 | 2012-09-19 | 2020-05-26 |
| HIGH Altitude CArdiovascular REsearch in the ANDES Telmisartan, Nifedipine, placebo - Hypertension, High Altitude | Phase 4 | Completed | Istituto Auxologico Italiano | 100 | 2012-05-01 | 2013-04-12 |
Showing 20 of 69. Sign in to see all of them.
Hypertension (45) · Essential Hypertension (6) · Renal Insufficiency, Chronic (5) · Cardiovascular Diseases (4) · Coronary Artery Disease (4) · Diabetes Mellitus, Type 2 (4) · Diabetic Nephropathies (4) · Metabolic Syndrome (4) · Stroke (3) · Atrial Fibrillation (2) · COVID-19 (2) · Hyperkalemia (2) · Proteinuria (2) · Acute Coronary Syndrome (1) · Albuminuria (1)
Boehringer Ingelheim (26) · Yuhan Corporation (4) · Chong Kun Dang Pharmaceutical (3) · University of Vigo (2) · Aligarh Muslim University (1) · Aristotle University Of Thessaloniki (1) · Bayer (1) · Baylor Research Institute (1) · Biomedis International Ltd. (1) · Catholic University of the Sacred Heart (1) · China National Center for Cardiovascular Diseases (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · Coordinación de Investigación en Salud, Mexico (1) · Heart Care Foundation (1) · Istituto Auxologico Italiano (1)
South Korea (15) · Germany (11) · United States (11) · Spain (10) · China (8) · France (8) · Italy (8) · Canada (6) · Japan (6) · Denmark (5) · Mexico (5) · Australia (4) · Austria (4) · Brazil (4) · Ireland (4)
Ramon C Hermida, PhD (2) · Alfonso M. M Cueto-Manzano, MD, MSc, PhD (1) · BeomSeok Kim, M.D, Ph.D (1) · Do-Sun Lim, MD, PhD (1) · Fazilatunnesa Malik, MBBS, FCPS (1) · Gennaro Cice, MD (1) · Gianfranco Parati, MD, PhD (1) · Hirofumi Soejima, MD, PhD (1) · Hisao Ogawa, Prof., MD, PhD (1) · Hyo-Soo Kim, Professor (1)
PMID 38682786, PMID 32905623, PMID 36398903, PMID 17339550, PMID 18378520, PMID 18496508, PMID 18537808, PMID 18707986, PMID 18753638, PMID 18753639, PMID 18757085, PMID 18757238, PMID 19407805, PMID 19451556, PMID 19463506, PMID 19506526, PMID 19683638, PMID 19770395, PMID 20231536, PMID 20980201, PMID 21070920, PMID 21200437, PMID 21252701, PMID 21263104, PMID 21357827, PMID 21617110, PMID 21700754, PMID 21788624, PMID 21884956, PMID 21947289, PMID 22089721, PMID 22192672, PMID 22267825, PMID 22329591, PMID 22495138, PMID 22525206, PMID 22552566, PMID 22717420, PMID 22738922, PMID 22829023, PMID 22922507, PMID 23184565, PMID 23212996, PMID 23282123, PMID 23630950, PMID 23895814, PMID 23939297, PMID 23988639, PMID 24191305, PMID 24356937
2008 (1), 2009 (1)